SWOG clinical trial number
C9741

A Randomized Phase III Trial of Sequential Chemotherapy Using Doxorubicin, Paclitaxel, and Cyclophosphamide or Concurrent Doxorubicin and Cyclophosphamide Followed by Paclitaxel at 14 or 21 Day Intervals in Women with Node Positive Stage II/IIIA Breast Cancer

Closed
Phase
Published
Abbreviated Title
Sequential vs. concurrent Tx in Stage II/IIA Breast
Activated
07/01/1998
Closed
03/31/1999
Participants
NCORP, Members, Medical Oncologists, Pathologists, Affiliates

Research committees

Breast Cancer

Treatment

Cyclophosphamide Allopurinol Fludarabine Phosphate Rituximab CC-5013 (Lenalidomide)

Other Clinical Trials

S2206
SWOG Clinical Trial Number

A Randomized trial of neoadjuvant durvalumab plus chemotherapy versus chemotherapy alone for Adults with MammaPrint Ultrahigh (MP2) hormone receptor (HR) positive /Human Epidermal Growth Factor receptor (HER2) negative stage II-III breast cancer

Research Committee(s)
Breast Cancer
Symptom Control and Quality of Life
Activated
10/30/2023
17% Accrual
Accrual
17%
Open
Phase
S2212
SWOG Clinical Trial Number

TIL Adapted Neo adjuvant Chemotherapy Optimization in Triple negative breast cancer (SCARLET)

Research Committee(s)
Breast Cancer
Activated
07/21/2023
26% Accrual
Accrual
26%
Open
Phase
CTSU/NRG-BR007
SWOG Clinical Trial Number

A Phase III Clinical Trial Evaluating De-escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score </= 18 Breast Cancer

Research Committee(s)
Breast Cancer
Activated
06/07/2021
Open
Phase